Full Press Release Details
Subsidiary OphthaliX Provides an Update on its Clinical Developments and Strategic Plans
Petach Tikva, Israel, June 9, 2014 /
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule
drugs that address inflammatory and cancer diseases, announced today that its subsidiary, OphthaliX, Inc., has issued an update
on its clinical developments and strategic plans:
CF101, an A3 adenosine receptor (A3AR) agonist, is a novel,
first in class small molecule orally bioavailable drug which binds with high affinity and selectivity to the A3AR, which is known
to be over-expressed in inflammatory cells. The drug acts as a neuro-protective agent and prevents apoptosis of retinal ganglion
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE MKT: CANF)
(CFBI.TA) is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion
dollar markets in the treatment of cancer and inflammatory diseases. The Company's CF101 is in Phase II/III trials for the treatment
of psoriasis and the Company is preparing for a Phase III CF101 trial for rheumatoid arthritis. Can-Fite's liver cancer drug CF102
is in Phase II trials and has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. CF102 has also shown
proof of concept to potentially treat other cancers including colon, prostate, and melanoma. These drugs have an excellent safety
profile with experience in over 1,200 patients in clinical studies to date. For more information please visit: www.can-fite.com
Forward-Looking Statements
This press release may contain forward-looking
statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts,
business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its
representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified
by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may,"
"should" or "anticipate" or their negatives or other variations of these words or other comparable words or
by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may
be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission (the
"SEC"), press releases or oral statements made by or with the approval of one of Can-Fite's authorized executive officers.
Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made.
Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks
and uncertainties that could cause Can-Fite's actual results to differ materially from any future results expressed or implied
by the forward-looking statements. Many factors could cause Can-Fite's actual activities or results to differ materially from the
activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in
Can-Fite's filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector
where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does
not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future
events or otherwise.